Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671488 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
A Phase 1 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01671488 is a Phase 1 study that was terminated before completion, run by Brown University. The registered enrollment target is 11 participants.
The verdict
NCT01671488, a Phase 1 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The main purpose of this study is to study the safety and effectiveness of ADXS11-001 when combined with standard chemotherapy and radiation treatment for anal cancer. ADXS11-001 is an investigational agent that is not approved by the FDA to treat anal cancer or any other cancer.
Interventions
- DRUG Mitomycin
- RADIATION IMRT
- DRUG 5FU
- BIOLOGICAL Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671488
The ClinicalTrials.gov registry entry for NCT01671488 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mitomycin is the first listed.
NCT01671488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671488 about?
NCT01671488 is a clinical study titled "A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer". The main purpose of this study is to study the safety and effectiveness of ADXS11-001 when combined with standard chemotherapy and radiation treatment for anal cancer. ADXS11-001 is an investigational agent that is not approved by the FDA to treat anal cancer or any other cancer.
What is the current status of trial NCT01671488?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-02. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01671488?
The interventions under investigation include: Mitomycin (DRUG), IMRT (RADIATION), 5FU (DRUG), Treatment (BIOLOGICAL).
Who is sponsoring clinical trial NCT01671488?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.